- Data from study of EpiSwitch™ suggest independent predictive power of the 3D genome architecture technology platform in immuno-oncology
- Posters presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting co-authored by scientists from Merck KGaA, Darmstadt, Germany, Pfizer and Mayo Clinic
PR Newswire
OXFORD, United Kingdom, Nov. 8, 2019